AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...